About
Oral Mucosal Immunotherapy
Areas of Focus
Categories
Drug Delivery & FormulationNJ, NY, PA
Team (8)
Christopher R. Schuster, MBA
Chief Financial Officer
Intrommune Therapeutics
executive
Michael Nelson, JD
CEO & Board Member
Intrommune Therapeutics
executive
Michelle Mantia
Controller
Intrommune Therapeutics
team_member
Miles McLennan
Head of Clinical Operations
Intrommune Therapeutics
team_member
Nandini Murthy
Head of Regulatory
Intrommune Therapeutics
team_member
Nicole Faris
Strategic Director, Medical Affairs & Clinical Development
Intrommune Therapeutics
team_member
Clinical Trials (1)
View allTotal Trials
1
As Lead Sponsor
1
As Collaborator
0
Total Enrollment
32
By Phase
PHASE1: 1
By Status
COMPLETED: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...